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Biomarkers for Alzheimer’s disease (AD) such as hippocampal atrophy and abnormal 
concentrations of cerebrospinal fluid (CSF) amyloid p42 (Ap42), phosphorylated tau181 (p-tau) 
and total tau (t-tau) have become established tools in the diagnostic work-up of patients 
suspected of dementia. Recently, AD research has seen a shift in focus towards the prodromal 
and preclinical stages of this disease, at the same time creating a shift in emphasis from 
clinical criteria towards biomarkers that represent core features of AD. The CSF biomarkers 
Ap42, p-tau and t-tau are promising candidates, as they reflect the neuropathologic features of 
AD and research indicates they become abnormal early in the disease process. However, data 
are currently lacking regarding the exact timing of these biomarkers becoming abnormal, and 
the order in which these events happen. Longitudinal studies to elucidate the dynamics of this 
process are still ongoing, but several hypothetical models have been proposed. These models 
are relevant in providing a framework for further research, for example to establish a 
paradigm in which biomarker changes over time could become surrogate end-points in 
disease modification trials. In addition, biomarker dynamics might provide information on 
disease stage and progression once these models have been confirmed.
An interesting feature that these models have in common is that they make a clear 
distinction between the moment that CSF Ap42 becomes abnormal and the moment that CSF 
tau becomes abnormal. Amyloid deposition (resulting in reduced levels of CSF Ap42) is 
suggested to be the earliest event, occurring long before cognitive symptoms are apparent, 
and plateauing early in the disease. Tau on the other hand is suggested to become abnormal 
much later, when clinical symptoms are already present, and to continue to increase in 
patients who progress from mild cognitive impairment (MCI) to moderate and severe 
dementia.1,2
We question this distinction in timing between amyloid and tau. To illustrate that these 
models can be challenged by empirical data, we present a case of early-onset AD with the
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longest follow-up of CSF biomarkers reported in the literature. During the nine years between 
the earliest clinical manifestation and advanced dementia, we noted no essential changes in 
CSF Ap42, p-tau and t-tau. At age 53, this man presented with a mild memory disorder 
objectified by neuropsychological testing. Neuroimaging (CT cerebrum) was normal, but CSF 
analysis showed abnormal results: 294 pg/ml (reference value >500 pg/ml), phosphorylated 
tauigi (p-tau) 141 pg/ml (<85 pg/ml), and t-tau 660 pg/ml (<350 pg/ml).3 No interference with 
activities of daily living was established and MCI was diagnosed. Over the next four years he 
gradually progressed -  confirmed by repeated neuropsychological evaluation -  to a diagnosis 
of probable AD, Clinical Dementia Rating (CDR) 1. Nine years after first contact, we re­
evaluated this patient, now progressed to CDR 2, with marked brain atrophy on CT. Lumbar 
puncture showed Ap42 399 pg/ml, p-tau 108 pg/ml, t-tau 655 pg/ml.
This case suggests that either there is no delay between changes in CSF Ap42, p-tau 
and t-tau, or that the change in tau occurs much earlier than suggested, that is, already in the 
preclinical stage. Studies in MCI patients support this by showing that both CSF Ap42 and tau 
are already abnormal in those patients who progressed to AD at follow up.4 We observed no 
further decrease in Ap4 2  or increase in p-tau or t-tau during disease progression in this case. 
This observation is supported by the few longitudinal studies performed so far in MCI and 
AD patients -  albeit with a much shorter follow up of 2 years -  that show a remarkable 
stability of CSF Ap42 and t-tau concentrations.4,5 This argues against the assumption that a 
change in pathological direction of these biomarkers could be of use as surrogate markers to 
reflect progression of disease.
This case questions models built largely on cross-sectional data. Inter-individual 
differences in progression rate and disease duration at diagnosis make cross-sectional studies 
unsuitable for inferences about the timing and order of events. Longitudinal studies covering 
the full spectrum of the disease, with measurement of imaging and biochemical markers, will
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be needed before a valid temporal model can be constructed. We speculate, however, that 
such studies will fail to demonstrate a clear distinction between the timing of Aß42 and tau 
becoming abnormal. Likely, they will demonstrate a lack of relevant CSF Aß42, p-tau and t- 
tau changes over time in the transition from early MCI to AD.
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